MedTrace Logo

Oral Colchicine in Argentina to Prevent Restenosis

NCT04382443 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 410

Last updated 2025-07-14

No results posted yet for this study

Summary

The Oral treatment of Colchicine in Argentina (ORCA) trial is a prospective, randomized, multicenter trial to included 450 patients with indication for myocardial revascularization with PCI between a group to be treated with BMS plus oral colchicine (OC) for three months, which should be administered at the time of PCI, these patients they would receive 0.5 mg twice a day per 3 months compared to the other group of patients who will be treated exclusively with last generation of DES.

Conditions

Interventions

DRUG

Colchicine

At the moment of BMS implantation intervention will mean that this group will receive colchicine as described.

Sponsors & Collaborators

  • Centro de estudios en Cardiologia Intervencionista

    lead OTHER

Principal Investigators

  • Alfredo E Rodriguez, MD, PhD · Centro de estudios en Cardiologia Intervencionista

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
110 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-12
Primary Completion
2022-04-30
Completion
2022-04-30

Countries

  • Argentina

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04382443 on ClinicalTrials.gov